Condition: Takayasu Arteritis · Tocilizumab · Adalimumab · Sponsor: Shanghai Zhongshan Hospital
Takayasu arteritis (TAK) is a rare chronic inflammatory arteritis, which lacks an effective well-accepted intervention strategy. We classify TAK patients into 3 levels, including mild, moderate, and severe. And the biological agents tocilizumab and adalimumab are randomly prescribed in severe patients, to find out the relatively better treatment strategy, facilitating better intervention strategy in severe TAK patients.
This description comes directly from the study's public registry record.
Rongyi Chen, PhD · +8615221160538 · chenry825@hotmail.com
Lili Ma, PhD · +8615221160538 · zsh-rheum@hotmail.com
Always discuss trial participation with your own doctor first.
| Department of Rheumatology in Zhongshan hospital, Fudan University | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04300686